Company Analysis
Sign in

Radiopharm Theranostics Limited (RADX)

Nasdaq: RADX · Pharmaceutical Preparations · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.7
◀ Past 7.9● Present 4.0▶ Future 5.8
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$3.6M+1114.3%
Net incomen/a
Earnings per share$-1.76+85.8%
Operating cash flow-$36.6M-59.5%
Cash$29.1M+56.8%
Debtn/a
Shareholders’ equity$42.9M+56.7%
Shares, diluted2.08B
Return on equityn/a
The recordfrom its filings
Filings in 202662
Newest filingNov 12 · 6-K
Annual reportSep 30, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Oct 27, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton RADX · research, not advice